Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced that Dr. Robert Ang, the President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 2:20 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced that Dr. Robert Ang, the President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 2:20 PM ET. A live webcast will be available on the Company's website, with an archived replay following the conference. Vor Biopharma focuses on changing the standard of care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies post-transplant.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -7.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.
11th Annual SVB Leerink Global Healthcare Conference
Date: Friday, February 18, 2022
Time: 2:20 PM ET
A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Sarah Spencer
Vice President, Corporate Communications, Vor
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.